Sign in

    Michaela Smith

    Research Analyst at Canaccord Genuity

    Michaela Smith is an Equity Research Associate at Canaccord Genuity, based in Vancouver, British Columbia, specializing in equity research and analysis across Canadian public companies. Her professional experience centers on supporting lead analysts in the evaluation and coverage of specific firms within her assigned sectors, with particular attention to detailed financial analysis and the preparation of investment recommendations. Michaela began her tenure at Canaccord Genuity in her current role and is based in Vancouver, British Columbia, but no prior employment information or extended career timeline was found. While explicit performance metrics, tracked companies, or publicly listed credentials could not be verified from available sources, her responsibilities and title suggest involvement in supporting equity research calls and regulatory compliance typical for junior equity research professionals.

    Michaela Smith's questions to Alphatec Holdings (ATEC) leadership

    Michaela Smith's questions to Alphatec Holdings (ATEC) leadership • Q2 2025

    Question

    Representing Caitlin Cronin, Michaela Smith asked for more color on where the impact of the raised full-year guidance would be seen in the second half and for any updates to free cash flow expectations.

    Answer

    CFO Todd Koning clarified that the guidance increase would primarily be reflected in Q3 results. He reiterated the free cash flow forecast, expecting a positive $1 million to $5 million in Q3 and positive cash flow for the full year 2025, stating that the company's performance continues to give them confidence in delivering on their commitments.

    Ask Fintool Equity Research AI

    Michaela Smith's questions to Alphatec Holdings (ATEC) leadership • Q1 2025

    Question

    Michaela Smith, on for Caitlin Cronin, asked if ATEC has plans to address the interventionalist call point, noting recent M&A activity in that space by other companies.

    Answer

    Executive Patrick Miles gave a definitive 'no,' stating that ATEC's business is exclusively focused on the spine surgeon. He expressed a strong conviction that expanding into the interventionalist or pain management space would be a 'huge mistake' and a distraction from the company's core mission and aligned interests with its surgeon customers and sales force.

    Ask Fintool Equity Research AI

    Michaela Smith's questions to KORU Medical Systems (KRMD) leadership

    Michaela Smith's questions to KORU Medical Systems (KRMD) leadership • Q4 2024

    Question

    Michaela Smith, on behalf of Caitlin Cronin, inquired about the expected business impacts from tariffs on manufacturing, supply chain costs, and the international business.

    Answer

    CFO Tom Adams stated that the impact is relatively immaterial as production is in the U.S. and Nicaragua. He noted a slight impact from some components procured from Mainland China, which has been factored into guidance. He quantified this impact as an approximate 0.5 percentage point headwind on the full-year gross margin.

    Ask Fintool Equity Research AI